Skip to content
Screener

Reported November 12, 2026 · Before market open

Revenue$2.1MBeat by $1.7M
EPS-$0.36In line
Revenue estimate$375.0K
EPS estimate-$0.36
“The updated results presented at ESMO further reinforce our confidence in the depth and consistency of desmoid tumor responses, alongside a favorable safety and tolerability profile. With our Phase 3 dosing, regimen and trial design aligned with the FDA, we are well positioned to initiate PEDESTAL in the first half of 2027, bringing us closer to delivering a potentially transformative treatment for patients with desmoid tumors.”
Mathai Mammen

Next report

Feb 11, 2027 (in 3 months)
Revenue estimate$1.1M
EPS estimate-$0.42

Financials

Q3 2026

Income statement

See full
Revenue$2.1M—
Operating income-$54.7M—
Net income-$44.5M—
EPS (diluted)-$0.36—

Balance sheet

See full
Cash & equivalents$521.2M—
Total debt$41.1M—
Total equity$1.0B—
Total assets$1.1B—

Cash flow

See full
Operating cash flow-$41.1M—
CapEx$611.0K—
Free cash flow-$41.7M—

Valuation & ratios

Valuation

as of 11/10/26
See full
Market cap$3.75B+4.2%
Enterprise value$3.27B—

Returns & leverage

See full
Debt / equity0×—
Current ratio12.9×—

Versus estimates

Revenue

Q3 2026$2.1MBeat by $1.7M
Q2 2026$100.0KMiss by $16.6M

Diluted EPS

Q3 2026-$0.36In line
Q2 2026-$2.32Miss by $2.16

FAQ

When did Parabilis Medicines report Q3 2026 earnings?
Parabilis Medicines (PBLS) reported Q3 2026 earnings on November 12, 2026 before market open.
What were Parabilis Medicines's Q3 2026 revenue and EPS?
Parabilis Medicines reported revenue of $2.1M and eps of $-0.36 for Q3 2026.
Did Parabilis Medicines beat estimates in Q3 2026?
Revenue beat the consensus estimate of $375.0K by $1.7M. EPS beat the consensus estimate of $-0.36 by $0.00.
Where can I find Parabilis Medicines's Q3 2026 SEC filings?
You can read the 8-K earnings release (0001193125-26-456892) and the 10-Q periodic report (0001193125-26-458388) directly on SEC EDGAR. The filing index links above go to sec.gov.